[1]
Roest AM, de Vries YA, Lim CCW, Wittchen HU, Stein DJ, Adamowski T, Al-Hamzawi A, Bromet EJ, Viana MC, de Girolamo G, Demyttenaere K, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Caldas-de-Almeida JM, Kawakami N, Lépine JP, Levinson D, Medina-Mora ME, Navarro-Mateu F, O'Neill S, Piazza M, Posada-Villa JA, Slade T, Torres Y, Kessler RC, Scott KM, de Jonge P, WHO World Mental Health Survey Collaborators. A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. Depression and anxiety. 2019 Jun:36(6):499-510. doi: 10.1002/da.22885. Epub 2019 Feb 6
[PubMed PMID: 30726581]
Level 3 (low-level) evidence
[2]
Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27:328(24):2431-2445. doi: 10.1001/jama.2022.22744. Epub
[PubMed PMID: 36573969]
[3]
Asmundson GJ, Taylor S, Smits JA. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depression and anxiety. 2014 Jun:31(6):480-6. doi: 10.1002/da.22277. Epub 2014 May 27
[PubMed PMID: 24865357]
Level 3 (low-level) evidence
[4]
Noyes R Jr, Crowe RR, Harris EL, Hamra BJ, McChesney CM, Chaudhry DR. Relationship between panic disorder and agoraphobia. A family study. Archives of general psychiatry. 1986 Mar:43(3):227-32
[PubMed PMID: 3954542]
[5]
Nocon A, Wittchen HU, Beesdo K, Brückl T, Hofler M, Pfister H, Zimmermann P, Lieb R. Differential familial liability of panic disorder and agoraphobia. Depression and anxiety. 2008:25(5):422-34
[PubMed PMID: 18023003]
[6]
Remmerswaal KCP, Ten Have M, de Graaf R, van Balkom AJLM, Penninx BWJH, Batelaan NM. Risk factors of chronic course of anxiety and depressive disorders: a 3-year longitudinal study in the general population. Social psychiatry and psychiatric epidemiology. 2024 Sep:59(9):1607-1615. doi: 10.1007/s00127-023-02591-0. Epub 2023 Nov 28
[PubMed PMID: 38015237]
[7]
Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depression and anxiety. 2010 Feb:27(2):113-33. doi: 10.1002/da.20646. Epub
[PubMed PMID: 20143426]
[8]
Prince EJ, Siegel DJ, Carroll CP, Sher KJ, Bienvenu OJ. A longitudinal study of personality traits, anxiety, and depressive disorders in young adults. Anxiety, stress, and coping. 2021 May:34(3):299-307. doi: 10.1080/10615806.2020.1845431. Epub 2020 Nov 15
[PubMed PMID: 33190525]
[9]
Bienvenu OJ, Brown C, Samuels JF, Liang KY, Costa PT, Eaton WW, Nestadt G. Normal personality traits and comorbidity among phobic, panic and major depressive disorders. Psychiatry research. 2001 May 10:102(1):73-85
[PubMed PMID: 11368842]
[10]
Bienvenu OJ, Samuels JF, Costa PT, Reti IM, Eaton WW, Nestadt G. Anxiety and depressive disorders and the five-factor model of personality: a higher- and lower-order personality trait investigation in a community sample. Depression and anxiety. 2004:20(2):92-7
[PubMed PMID: 15390211]
[11]
Hayward C, Wilson KA. Anxiety sensitivity: a missing piece to the agoraphobia-without-panic puzzle. Behavior modification. 2007 Mar:31(2):162-73
[PubMed PMID: 17307933]
[12]
Bienvenu OJ, Stein MB, Samuels JF, Onyike CU, Eaton WW, Nestadt G. Personality disorder traits as predictors of subsequent first-onset panic disorder or agoraphobia. Comprehensive psychiatry. 2009 May-Jun:50(3):209-14. doi: 10.1016/j.comppsych.2008.08.006. Epub 2008 Oct 21
[PubMed PMID: 19374963]
[13]
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H -U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International journal of methods in psychiatric research. 2012 Sep:21(3):169-84. doi: 10.1002/mpr.1359. Epub 2012 Aug 1
[PubMed PMID: 22865617]
[14]
Preti A, Piras M, Cossu G, Pintus E, Pintus M, Kalcev G, Cabras F, Moro MF, Romano F, Balestrieri M, Caraci F, Dell'Osso L, Sciascio GD, Drago F, Hardoy MC, Roncone R, Faravelli C, Musu M, Finco G, Nardi AE, Carta MG. The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy. Psychiatry investigation. 2021 Apr:18(4):277-283. doi: 10.30773/pi.2020.0342. Epub 2021 Apr 15
[PubMed PMID: 33849246]
Level 2 (mid-level) evidence
[15]
Wittmann A, Schlagenhauf F, Guhn A, Lueken U, Gaehlsdorf C, Stoy M, Bermpohl F, Fydrich T, Pfleiderer B, Bruhn H, Gerlach AL, Kircher T, Straube B, Wittchen HU, Arolt V, Heinz A, Ströhle A. Anticipating agoraphobic situations: the neural correlates of panic disorder with agoraphobia. Psychological medicine. 2014 Aug:44(11):2385-96. doi: 10.1017/S0033291713003085. Epub 2014 Jan 7
[PubMed PMID: 24398049]
[16]
Indovina I, Cacciola A, Delle Monache S, Milardi D, Lacquaniti F, Toschi N, Cochereau J, Bosco G. A case report of agoraphobia following right parietal lobe surgery: changes in functional and structural connectivities of the multimodal vestibular network. Frontiers in neurology. 2023:14():1163005. doi: 10.3389/fneur.2023.1163005. Epub 2023 May 12
[PubMed PMID: 37251237]
Level 3 (low-level) evidence
[17]
Zucchelli MM, Piccardi L, Nori R. The Fear to Move in a Crowded Environment. Poor Spatial Memory Related to Agoraphobic Disorder. Brain sciences. 2021 Jun 16:11(6):. doi: 10.3390/brainsci11060796. Epub 2021 Jun 16
[PubMed PMID: 34208661]
[18]
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine. 2006 May 22:166(10):1092-7
[PubMed PMID: 16717171]
[19]
Lambe S, Bird JC, Loe BS, Rosebrock L, Kabir T, Petit A, Mulhall S, Jenner L, Aynsworth C, Murphy E, Jones J, Powling R, Chapman K, Dudley R, Morrison A, Regan EO, Yu LM, Clark D, Waite F, Freeman D. The Oxford Agoraphobic Avoidance Scale. Psychological medicine. 2023 Mar:53(4):1233-1243. doi: 10.1017/S0033291721002713. Epub 2021 Aug 23
[PubMed PMID: 37010211]
[20]
Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depression and anxiety. 2018 Jun:35(6):502-514. doi: 10.1002/da.22728. Epub 2018 Feb 16
[PubMed PMID: 29451967]
Level 1 (high-level) evidence
[21]
Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. The American journal of psychiatry. 2001 Dec:158(12):1989-92
[PubMed PMID: 11729014]
[22]
Plag J, Petzold MB, Gechter J, Liebscher C, Ströhle A. Patients' characteristics and their influence on course of fear during agoraphobic symptom provocation: may SS(N)RI treatment compensate unfavorable individual preconditions? Nordic journal of psychiatry. 2018 Jul:72(5):325-335. doi: 10.1080/08039488.2018.1457178. Epub 2018 Apr 12
[PubMed PMID: 29644923]
[23]
Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. The Cochrane database of systematic reviews. 2016 Oct 12:10(10):CD011170
[PubMed PMID: 27730622]
Level 1 (high-level) evidence
[24]
Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Advances in experimental medicine and biology. 2020:1191():347-365. doi: 10.1007/978-981-32-9705-0_19. Epub
[PubMed PMID: 32002937]
Level 3 (low-level) evidence
[25]
Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta psychiatrica Scandinavica. 2002 Sep:106(3):163-7
[PubMed PMID: 12197851]
Level 1 (high-level) evidence
[26]
Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychological medicine. 1991 Nov:21(4):991-8
[PubMed PMID: 1685792]
Level 1 (high-level) evidence
[27]
Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and anxiety. 2007:24(1):1-14
[PubMed PMID: 16894619]
Level 1 (high-level) evidence
[28]
Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, Thakkinstian A. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical research ed.). 2022 Jan 19:376():e066084. doi: 10.1136/bmj-2021-066084. Epub 2022 Jan 19
[PubMed PMID: 35045991]
Level 1 (high-level) evidence
[29]
Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. The Cochrane database of systematic reviews. 2007 Jan 24:2007(1):CD004364
[PubMed PMID: 17253502]
Level 1 (high-level) evidence
[30]
Perugi G, Frare F, Toni C. Diagnosis and treatment of agoraphobia with panic disorder. CNS drugs. 2007:21(9):741-64
[PubMed PMID: 17696574]